The market for physician-supervised online GLP-1 programs has matured considerably since 2022, when a handful of telehealth platforms were racing to meet explosive demand for semaglutide access. In 2026, the landscape includes dozens of programs across a wide range of price points, clinical models, and quality standards. Choosing between them is not straightforward — and the features that matter most from a clinical standpoint are rarely the ones that appear most prominently in advertising.
This evaluation applies a consistent clinical framework to the four physician-supervised programs that DawaMed has vetted for quality, transparency, and nationwide availability. It is independent: DawaMed may earn a referral fee if you enroll through a link on this site, but that relationship does not influence this ranking or how each program is characterized. Our affiliate disclosure is available at /disclosure.
What makes a GLP-1 program clinically sound?
- Prescribing by a licensed physician or NP in the patient's state of residence
- Complete health intake screening for contraindications and drug interactions
- Structured dose escalation protocol (not initiating at maintenance dose)
- Dispensing from a licensed pharmacy (503A, 503B, or retail)
- Ongoing clinical monitoring and access to providers during treatment
- Transparent pricing before enrollment — no hidden fees revealed post-signup
The Clinical Evidence Foundation: What We Are Working With
Before evaluating platforms, context on the clinical evidence is warranted. The outcomes data underpinning all GLP-1 weight loss programs derives primarily from two landmark trial programs:
For semaglutide: the STEP program — four phase 3 randomized controlled trials demonstrating 14.9% mean weight loss over 68 weeks (STEP 1, n=1,961) in adults without diabetes, 9.6% loss with type 2 diabetes (STEP 2), and 16% loss combined with intensive lifestyle intervention (STEP 3).1 The SELECT trial further established semaglutide's 20% reduction in major cardiovascular events in high-risk patients.2
For tirzepatide: the SURMOUNT program — with SURMOUNT-1 (n=2,539) demonstrating mean weight losses of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg weekly doses respectively over 72 weeks, with 91% of participants at the 15 mg dose achieving at least 5% weight loss.3 The head-to-head SURMOUNT-5 trial (published 2025) showed tirzepatide outperformed semaglutide on weight reduction endpoints over 72 weeks in adults without diabetes.4
These trials establish the clinical potential of the drug class. Platform evaluation then becomes a question of: which programs give patients the best chance of achieving outcomes consistent with this evidence base, under appropriate medical supervision, at a sustainable cost?
Find a GLP-1 option that fits your budget in under 60 seconds.
Take the Free Quiz →Program Evaluation
Ro Body Program — Best for Insurance Navigation
All-in cash-pay cost: From $294/month ($45 first month + $145/month membership + medication from $149–$449/month depending on drug and dose). With insurance approval: from $145–$195/month (membership + copay).
Medications available: Wegovy (semaglutide 2.4 mg injectable and oral), Zepbound (tirzepatide), Ozempic, Foundayo (orforglipron — the oral non-peptide GLP-1 agonist approved in 2026), and compounded semaglutide as a clinical fallback.
Clinical model: Initial physician consultation, quarterly clinical check-ins, weekly RN health coaching, metabolic lab work through Quest Diagnostics or at-home kit, and an active insurance concierge service that handles prior authorization and appeals on the patient's behalf.
Clinical strengths: Ro's insurance concierge infrastructure is the most developed of any platform evaluated here. For commercially insured patients who meet clinical criteria for Wegovy or Zepbound, the concierge service has a demonstrated track record of securing prior authorization — including on appeal following initial denial. If approved, effective costs drop to the $145–$195/month range, making brand-name FDA-approved medications accessible at prices comparable to compounded alternatives. This is the most clinically significant differentiator Ro offers. Lab monitoring inclusion is also noteworthy: baseline metabolic labs before initiating GLP-1 therapy (including HbA1c, comprehensive metabolic panel, and lipid panel) represent standard of care that is not universally included in lower-cost programs.
Limitations: The membership-plus-medication cost structure creates initial pricing complexity. The first month introductory pricing has led some patients to underestimate ongoing all-in costs. Coaching quality receives mixed reviews — some patients find the RN check-ins substantive; others experience them as administrative.
Best suited for: Commercially insured patients seeking brand-name FDA-approved medications, particularly those with cardiovascular risk factors for whom the SELECT trial's cardioprotective data is clinically relevant. Patients with complex medical histories who benefit from included lab monitoring and physician oversight.
Hims & Hers Weight Loss — Most Established Consumer Platform
Cash-pay cost: From $199/month for compounded semaglutide on multi-month plans paid upfront. Brand-name Wegovy from $298/month; oral Wegovy from $145/month at lower doses.
Medications available: Compounded semaglutide injectable (46 states — excludes Alabama, Arkansas, Louisiana, Mississippi for compounded formulation); brand-name Wegovy, Ozempic, Zepbound; oral medication combination kits.
Clinical model: Physician evaluation, ongoing prescription management, 24/7 messaging access to care team. Hims has been operating at significant scale since 2018 across multiple health categories, with over 2.4 million active subscribers across its total platform.
Clinical strengths: Platform stability and established clinical infrastructure. Hims has navigated multiple regulatory cycles in telehealth and has maintained compliant operations across its product lines. The 24/7 care team messaging model provides accessible clinical touchpoints for patients with questions during treatment. Breadth of medication options — including both compounded and brand-name pathways — gives prescribers clinical flexibility to match patients to appropriate formulations. The multi-month upfront pricing for compounded semaglutide results in lower effective monthly costs for patients who commit to treatment.
Limitations: Compounded semaglutide requires upfront multi-month payments, creating financial commitment before patients know how they will respond to therapy. The 46-state availability for compounded semaglutide excludes some patients. State-by-state regulatory changes affecting compounded GLP-1 access can affect plan availability without significant advance notice.
Best suited for: Patients in eligible states seeking an established platform with both compounded and brand-name options, particularly those who prefer flexibility between oral and injectable formulations.
Fridays Health — Best All-In Pricing with Integrated Coaching
Cash-pay cost: From $199/month. Transparent all-in pricing: no separate membership fee stacked on top of medication cost.
Medications available: GLP-1 medications determined by physician evaluation. Available in all 50 states.
Clinical model: Physician evaluation and prescribing, GLP-1 medication access, weekly behavioral coaching integrated into the program at the base price. FSA/HSA eligible. 4.7-star patient-reported rating.
Clinical strengths: The integrated coaching model reflects an important clinical reality that deserves emphasis: GLP-1 medications produce substantially better long-term outcomes when combined with behavioral support. A systematic review published in Obesity Reviews (2022) found that lifestyle intervention combined with pharmacotherapy produced significantly greater weight loss maintenance than pharmacotherapy alone. Fridays builds this evidence-based component into the base price rather than treating it as an optional add-on — a clinically sound structural decision. The transparent all-in pricing eliminates a common source of patient frustration with multi-fee models. All-50-states availability removes geographic constraints.
Limitations: Less public information available about the specific physicians and compounding pharmacy partners compared to Ro and Hims. Patients who want maximum visibility into the clinical infrastructure behind their program may want to ask more detailed questions before enrolling.
Best suited for: Patients who want behavioral coaching integrated with medication at a transparent all-in price, and those who value lifestyle support as part of their treatment plan — which, clinically, is most patients.
Noom Med — Best Behavioral Science Integration
Cash-pay cost: From $149/month for the combined medication and behavioral program.
Medications available: GLP-1 medication access with physician evaluation. Wegovy access and behavioral program combined. Available in all 50 states.
Clinical model: Noom's platform was built around cognitive behavioral therapy (CBT)-based behavioral change tools before adding medication access. Noom Med combines physician-supervised GLP-1 medication with Noom's behavioral curriculum, AI-assisted food logging, and human coach support.
Clinical strengths: The evidence base for behavioral intervention in obesity management is substantial. CBT-based approaches have demonstrated efficacy in weight loss maintenance that complements pharmacotherapy, and emerging research suggests that patients with higher self-monitoring adherence on GLP-1 therapy achieve better long-term outcomes. Noom's behavioral science infrastructure is the most developed of any platform in this comparison. The starting price at $149/month is also the most accessible among physician-supervised options reviewed here.
Limitations: Noom's model requires active engagement with the behavioral program to realize its full value — patients seeking a purely medication-focused approach may find the program structure more intensive than desired. Patient engagement rates with digital health programs in general vary significantly, and Noom's outcomes data reflects participants who engage with the full program.
Best suited for: Patients motivated to understand the psychology and behavioral components of weight management, those starting GLP-1 therapy for the first time who want the most comprehensive support framework, and those for whom program price is a significant factor.
How to Choose: A Clinical Decision Framework
No single program is optimal for every patient. The following framework reflects how an obesity medicine specialist would approach this decision:
| Patient Profile | Recommended Starting Point | Reasoning |
|---|---|---|
| Commercially insured, BMI ≥30, no major comorbidities | Ro Body Program | Insurance concierge may secure brand-name coverage at $25–$50/month copay |
| Commercially insured with cardiovascular disease | Ro Body Program (brand-name Wegovy prioritized) | SELECT trial cardiovascular data applies to Wegovy's specific formulation |
| Uninsured or no GLP-1 coverage, wants coaching | Fridays Health or Noom Med | All-in transparent pricing with behavioral support included |
| Uninsured, primary concern is cost, has used weight-loss medication before | Noom Med (from $149/month) | Lowest verified price point with physician oversight |
| Needle-averse, seeking oral formulation | Hims & Hers (oral Wegovy) or Ro (oral Wegovy) | FDA-approved oral semaglutide now available through both platforms |
The most important principle across all options: begin with a physician-supervised program, maintain regular clinical contact during dose escalation, and build a plan for long-term treatment before initiating — because the clinical evidence strongly supports that ongoing therapy is required to maintain outcomes.